Market closed
Madrigal Pharmaceuticals/$MDGL
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Madrigal Pharmaceuticals
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.
Ticker
$MDGL
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
528
ISIN
US5588681057
Website
MDGL Metrics
BasicAdvanced
$6.3B
-
-$17.97
-0.69
-
Price and volume
Market cap
$6.3B
Beta
-0.69
52-week high
$377.46
52-week low
$200.63
Average daily volume
373K
Financial strength
Current ratio
5.908
Quick ratio
5.408
Long term debt to equity
16.711
Total debt to equity
16.854
Interest coverage (TTM)
-30.09%
Management effectiveness
Return on assets (TTM)
-25.56%
Return on equity (TTM)
-50.16%
Valuation
Price to revenue (TTM)
19.425
Price to book
8.83
Price to tangible book (TTM)
8.83
Price to free cash flow (TTM)
-15.358
Growth
Earnings per share change (TTM)
-22.59%
3-year earnings per share growth (CAGR)
7.05%
What the Analysts think about MDGL
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Madrigal Pharmaceuticals stock.
MDGL Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
MDGL Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
MDGL News
AllArticlesVideos
Madrigal Announces New Clinical Data Demonstrating Rezdiffra™ (resmetirom) Significantly Improved Multiple Noninvasive Tests and Portal Hypertension Risk in Patients with Compensated MASH Cirrhosis
GlobeNewsWire·5 days ago
Madrigal Pharmaceuticals: An Encouraging Start For Rezdiffra
Seeking Alpha·1 week ago
Madrigal Pharmaceuticals, Inc. (MDGL) Q1 2025 Earnings Call Transcript
Seeking Alpha·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Madrigal Pharmaceuticals stock?
Madrigal Pharmaceuticals (MDGL) has a market cap of $6.3B as of May 15, 2025.
What is the P/E ratio for Madrigal Pharmaceuticals stock?
The price to earnings (P/E) ratio for Madrigal Pharmaceuticals (MDGL) stock is 0 as of May 15, 2025.
Does Madrigal Pharmaceuticals stock pay dividends?
No, Madrigal Pharmaceuticals (MDGL) stock does not pay dividends to its shareholders as of May 15, 2025.
When is the next Madrigal Pharmaceuticals dividend payment date?
Madrigal Pharmaceuticals (MDGL) stock does not pay dividends to its shareholders.
What is the beta indicator for Madrigal Pharmaceuticals?
Madrigal Pharmaceuticals (MDGL) has a beta rating of -0.69. This means that it has an inverse relation to market volatility.